LENZ Therapeutics (LENZ) Stock Statistics & Valuation Metrics

LENZ Therapeutics has a market cap or net worth of $109.97M. The enterprise value is -$76.19M.

Market Cap

$109.97M

Enterprise Value

-$76.19M

LENZ Therapeutics has 31,420,584 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

31,420,584

Owned by Insiders

3.28%

Owned by Institutions

22.33%

LENZ Therapeutics’s return on equity (ROE) is -0.29 and return on invested capital (ROIC) is -31.96%.

Return on Equity (ROE)

-0.29

Return on Assets (ROA)

-0.27

Return on Invested Capital (ROIC)

-31.96%

Return on Capital Employed (ROCE)

-0.32

Revenue Per Employee

125.58K

Profits Per Employee

-540.31K

Employee Count

152

Asset Turnover

0.06

Inventory Turnover

0.00

The current PE Ratio of LENZ Therapeutics is -0.77. LENZ Therapeutics’s PEG ratio is 0.01.

PE Ratio

-0.77

PS Ratio

8.80

PB Ratio

0.57

Price to FCF

-0.85

Price to Operating Cash Flow

-0.85

PEG Ratio

0.01

In the last 12 months, LENZ Therapeutics had revenue of 19.09M and earned -82.13M in profits. Earnings per share was -2.85.

Revenue

19.09M

Gross Profit

18.38M

Operating Income

-91.14M

Pretax Income

-81.63M

Net Income

-82.13M

EBITDA

-81.34M

Earnings Per Share (EPS)

-2.85

In the last 12 months, operating cash flow was -127.63M and capital expenditures -72,000, giving a free cash flow of -127.70M billion.

Operating Cash Flow

-127.63M

Free Cash Flow

-127.70M

Free Cash Flow per Share

-4.06

LENZ Therapeutics pays an annual dividend of $7.21, resulting in a dividend yield of ―

Dividend Per Share

$7.21

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-133.70%

Earnings Yield

-146.85%

Beta

1.80

52-Week Price Change

-87.66%

50-Day Moving Average

4.04

200-Day Moving Average

7.64

Relative Strength Index (RSI)

48.80

Average Volume (3m)

877.55K

LENZ Therapeutics upcoming earnings date is Mar 24, 2027, TBA (Not Confirmed).

Last Earnings Date

Oct 28, 2026

Next Earnings Date

Mar 24, 2027

Ex-Dividend Date

Mar 22, 2024

LENZ Therapeutics as a current ratio of 14.23, with Debt / Equity ratio of 0.29%

Current Ratio

14.23

Quick Ratio

14.23

Debt to Market Cap

0.00

Net Debt to EBITDA

0.30

Interest Coverage Ratio

0.00

In the past 12 months, LENZ Therapeutics has paid 502.00K in taxes.

Income Tax

502.00K

Effective Tax Rate

-0.01

LENZ Therapeutics EV to EBITDA ratio is -0.46, with an EV/FCF ratio of -0.51.

EV to Sales

5.29

EV to EBITDA

-0.46

EV to Free Cash Flow

-0.51

EV to Operating Cash Flow

-0.51

LENZ Therapeutics has $197.30M in cash and marketable securities with $0.00 in debt, giving a net cash position of $197.30M billion.

Cash & Marketable Securities

$197.30M

Total Debt

$0.00

Net Cash

$197.30M

Net Cash Per Share

$6.28

Tangible Book Value Per Share

$6.11

Gross margin is 80.21%, with operating margin of -1211.17%, and net profit margin of -1134.97%.

Gross Margin

80.21%

Operating Margin

-1211.17%

Pretax Margin

-1134.93%

Net Profit Margin

-1134.97%

EBITDA Margin

-1148.05%

EBIT Margin

-1150.70%

The average price target for LENZ Therapeutics is $15.80, which is 11.43% higher than the current price. The consensus rating is Moderate Buy

Price Target

$15.80

Price Target Upside

356.65% Upside

Analyst Consensus

Moderate Buy

Analyst Count

6

Revenue Growth Forecast

-29.38%

EPS Growth Forecast

-112.65%

Smart Score

2

AI Score

53